ROIV · Large Cap · NASDAQ · Healthcare · Biotechnology
Free research brief
Free to track. No card required.
Price, momentum, and the numbers behind the story.
Overall score
47/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Lowest
$37.5
Median target
$41
Current price
$41.74
Highest
$50
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Debt / equity
Favorable · 0.02 - strong leverage
0.02x
Current ratio
Strong · Good liquidity position
16.72x
Price / sales
Rich · Overpriced by revenue
3349.81x
ROIC
Weak · Weak capital efficiency
-118.8%
ROE
Needs attention · Unfavorable
-8.5%
ROIV against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $25.23B | - | -67.6% | 47 | |
| $10.51B | 20.0 | +19.7% | 78 | |
| $33.17B | 34.7 | +15.5% | 78 | |
| $4.12B | 12.4 | +13.5% | 78 | |
| $1.08T | 39.1 | +49.6% | 77 |
Every story that touched the stock this week, newest first.